135 related articles for article (PubMed ID: 8343277)
1. Vinca alkaloids: anti-vascular effects in a murine tumour.
Hill SA; Lonergan SJ; Denekamp J; Chaplin DJ
Eur J Cancer; 1993; 29A(9):1320-4. PubMed ID: 8343277
[TBL] [Abstract][Full Text] [Related]
2. The effect of vinca alkaloids on tumour blood flow.
Hill SA; Lonergan SJ; Denekamp J; Chaplin DJ
Adv Exp Med Biol; 1994; 345():417-22. PubMed ID: 8079737
[No Abstract] [Full Text] [Related]
3. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid.
Hill SA; Sampson LE; Chaplin DJ
Int J Cancer; 1995 Sep; 63(1):119-23. PubMed ID: 7558438
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism.
Baguley BC; Holdaway KM; Thomsen LL; Zhuang L; Zwi LJ
Eur J Cancer; 1991; 27(4):482-7. PubMed ID: 1827725
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.
Holwell SE; Hill BT; Bibby MC
Br J Cancer; 2001 Jan; 84(2):290-5. PubMed ID: 11161390
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells.
King KL; Boder GB
Cancer Chemother Pharmacol; 1979; 2(4):239-42. PubMed ID: 455582
[TBL] [Abstract][Full Text] [Related]
7. Misonidazole reduces blood flow in two experimental murine tumours.
Murray JC; Randhawa VS
Br J Cancer; 1988 Aug; 58(2):128-32. PubMed ID: 3166901
[TBL] [Abstract][Full Text] [Related]
8. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro.
Himes RH; Kersey RN; Heller-Bettinger I; Samson FE
Cancer Res; 1976 Oct; 36(10):3798-802. PubMed ID: 954003
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of micronucleated polychromatic erythrocyte (MN-PCE) induction in vivo by aneuploidogens.
Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo V
Mutat Res; 2004 Dec; 565(1):79-87. PubMed ID: 15576241
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells.
Van Belle SJ; De Smet MC; De Mey JE; Storme GA
Anticancer Res; 1991; 11(1):465-71. PubMed ID: 2018383
[TBL] [Abstract][Full Text] [Related]
11. Metaphase accumulation in tumour isografts following the administration of colcemid, vinblastine or vincristine.
Smith SR; Thomas DB; Riches AC
J Anat; 1972 Apr; 111(Pt 3):480. PubMed ID: 5070809
[No Abstract] [Full Text] [Related]
12. Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts.
Hendriks HR; Langdon S; Berger DP; Breistøl K; Fiebig HH; Fodstad O; Schwartsmann G
Eur J Cancer; 1992; 28A(4-5):767-73. PubMed ID: 1524896
[TBL] [Abstract][Full Text] [Related]
13. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.
Chaplin DJ; Pettit GR; Parkins CS; Hill SA
Br J Cancer Suppl; 1996 Jul; 27():S86-8. PubMed ID: 8763854
[TBL] [Abstract][Full Text] [Related]
14. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
15. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
Noble CO; Guo Z; Hayes ME; Marks JD; Park JW; Benz CC; Kirpotin DB; Drummond DC
Cancer Chemother Pharmacol; 2009 Sep; 64(4):741-51. PubMed ID: 19184019
[TBL] [Abstract][Full Text] [Related]
16. Divalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.
Lobert S; Boyd CA; Correia JJ
Biophys J; 1997 Jan; 72(1):416-27. PubMed ID: 8994628
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules.
Binet S; Chaineau E; Fellous A; Lataste H; Krikorian A; Couzinier JP; Meininger V
Int J Cancer; 1990 Aug; 46(2):262-6. PubMed ID: 2200754
[TBL] [Abstract][Full Text] [Related]
18. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
Lobert S; Frankfurter A; Correia JJ
Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
[TBL] [Abstract][Full Text] [Related]
19. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
20. The action of two Vinca alkaloids on B16 melanoma in vitro.
Donoso JA; Himes RH
Cancer Biochem Biophys; 1984 Jun; 7(2):133-45. PubMed ID: 6467174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
